NASDAQ: CMPX

Compass Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CMPX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Compass Therapeutics, Inc. (NASDAQ: CMPX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 22:21 UTC.

What Compass Therapeutics, Inc. does

Cstone Pharmaceuticals is a clinical-stage biopharmaceutical company developing antibody-based therapeutics focused on treating cancer by targeting the relationships between angiogenesis, the immune system, and tumor growth. The company's pipeline includes four clinical-stage product candidates: tovecimig, a bispecific antibody targeting DLL4 and VEGF-A that is being evaluated in combination with paclitaxel for biliary tract cancer; CTX-471, an agonistic antibody targeting CD137 for various cancers; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1 currently in Phase 1 trials; and CTX-1…

Summarized from Compass Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-07-01
Return on equity	-39.43%

Charts

Charts are in the appInteractive charts for CMPX are available in Oxford Ledge.
Open CMPX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-02

2026-10-02Chief Accounting OfficerPurchase20,000$18.4K
2026-09-25Chief Accounting OfficerPurchase2,500$2.9K
2026-04-30General CounselPurchase25,000$47.2K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

TANG CAPITAL MANAGEMENT LLC17,990,782$39.40M+7.2%
ORBIMED ADVISORS LLC15,219,994$33.33M0.0%
MONTANOVA CAPITAL, LLC14,101,159$30.88M-1.4%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2024-12-10Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-05-28Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-04-24Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does Compass Therapeutics, Inc. do?

When did CMPX last file with the SEC?

Compass Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-01. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 22:21 UTC. This page is also available as JSON at /api/data?ticker=CMPX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CMPX and 5,000+ tickers.

Create a free account — keep CMPX

For your agent

GET /api/data?ticker=CMPX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt